Genomic Health (GHDX) says the designated national contractor for its Oncotype DX breast cancer...

|About: Genomic Health, Inc. (GHDX)|By:, SA News Editor

Genomic Health (GHDX) says the designated national contractor for its Oncotype DX breast cancer test has expanded its coverage policy for Medicare patients to include patients with a form of breast cancer called ductal carcinoma in situ. The decision follows publication recently of DCIS scores measured by the company's breast cancer test in the Journal of the National Cancer Institute, showing the test provided important information beyond traditional clinical factors.